Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine

American Journal of Gastroenterology

Volumn 101, Issue 11, 2006, Pages 2523-2529

  Flink, Hajo J ^a   Hansen, Bettina E ^a   Heathcote, E Jenny ^b   Feinman, S Victor ^c   Simsek, Halis ^d   Karayalcin, Selim ^e   Mach, Tomasz ^f   Leemans, Wim F ^a   De Man, Robert A ^a   Verhey, Elke ^a   Schalm, Solko W ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d HACETTEPE UNIVERSITY   (Turkey)

^e ANKARA UNIVERSITY   (Turkey)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2B;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERONS; LAMIVUDINE; MALE;

EID: 33750499091     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00812.x     Document Type: Article

References (17)

1. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-53.
3. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
4. van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: Relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.
5. Honkoop P, Niesters HG, de Man RA, et al. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-5.
6. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
7. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000;46:562-8.
8. Carreno V, Marcellin P, Hadziyannis S, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alpha-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999;30:277-82.
9. Janssen HL, Schalm SW, Berk L, et al. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol 1993;17(suppl 3):S47-51.
10. Munoz R, Castellano G, Fernandez I, et al. A pilot study of beta-interferon for treatment of patients with chronic hepatitis B who failed to respond to alpha-interferon. J Hepatol 2002;37:655-9.
11. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-26.
12. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alfa-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
13. Janssen H, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine as the treatment for HBeAg-positive chronic hepatitis B. Lancet 2005;365:123-9.
14. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
15. Pas SD, Fries E, De Man RA, et al. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000;38:2897-901.
16. Lau GKK, Piratvisuth T, Luo K-X, et al. Peginterferon alfa-2a (40kDa) (Pegasys) versus peginterferon alfa-2a plus lamivudine versus lamivudine in HBeAg-positive chronic HBV: Effect of previous treatment and drug exposure on sustained response. J Hepatol 2005;42(suppl 2):15.
17. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005;42:173-9.